Search

Displaying results 1771 - 1780 of 9314 in total
  1. Drug

    Carbetocin

    go.drugbank.com/drugs/DB01282
    ApprovedInvestigational

    It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus. … Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth.

  2. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]

  3. Drug

    Zafirlukast

    go.drugbank.com/drugs/DB00549
    Approved

    Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages … Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator.

    Categories: Agents to Treat Airway Disease
  4. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli.

  5. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    and the most common form of muscular dystrophy in the United States. … [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505]

  6. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral … Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy.

  7. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. … It was first approved by the FDA in 2017.

  8. Drug

    Inosine

    go.drugbank.com/drugs/DB04335
    Approved

    A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. … It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.

  9. Drug

    Coccidioides immitis spherule

    go.drugbank.com/drugs/DB11294
    Approved

    Coccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

  10. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    [A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. … Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.